Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

nds or feet, are estimated to affect more than one-third of people with psoriatic arthritis. At baseline, 78 percent (placebo group), 75 percent (golimumab 50 mg group) and 79 percent (golimumab 100 mg group) of study subjects presented with enthesitis (at least one tender body enthesitis site) as measured by the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) index modified for Psoriatic Arthritis; 34 percent (placebo group), 34 percent (golimumab 50 mg group) and 34 percent (golimumab 100 mg group) of subjects presented with dactylitis at baseline.

Both golimumab doses were significantly better than placebo in improvement of enthesitis as measured by percent change in the psoriatic arthritis modified MASES Index.

At week 14, the mean improvement in enthesitis was 44 percent among patients receiving golimumab 50 mg and 33 percent among patients receiving golimumab 100 mg, compared with a 19 percent worsening in patients receiving placebo (P < 0.001). At week 24, the mean improvements in enthesitis were 46 percent for patients receiving golimumab 50 mg and 52 percent among patients receiving golimumab 100 mg, compared with a 13 percent worsening in placebo patients (P < 0.001). The golimumab 100 mg dose significantly improved dactylitis measured by percent change in dactylitis score compared with placebo at week 14 (66 percent versus 5 percent; P = 0.009) and at week 24 (82 percent versus 28 percent; P < 0.001). There was a trend towards improvement in dactylitis for 50 mg golimumab dose at week 14 and 24 but the comparisons with placebo did not reach statistical significance.

In addition to improvements in joint symptoms, a substantial proportion of golimumab-treated patients experienced significant improvement in skin manifestations of the disease. Among a subset of the study population with at least three percent of body surface area involved by psoriasis at baseline, 40 percent and 58 percent of patients receiving golimumab 50 mg and
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... July 10, 2014   LabStyle Innovations Corp ... today announced the appointment of Professor Richard ... its Board of Directors. Prof. Stone ... experience to LabStyle as an entrepreneur, venture capitalist ... corporate governance expert. He currently serves on the ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
(Date:7/11/2014)... York, New York (PRWEB) July 11, 2014 ... http://www.transvaginalmeshlawsuithelp.com/ ) , filed against Johnson & Johnson’s ... courts, Bernstein Liebhard LLP notes that the Texas ... investigating the company’s marketing of surgical mesh products ... urinary incontinence. According to a report from kens5.com, ...
(Date:7/11/2014)... Butler Mobility has recently updated the paint color choices ... Previously the two standard colors were beige and brown. ... as standard colors at no additional charge! These colors ... enhance the beauty of the stairway. Homeowners will find ... individual décor. , The new selection of standard colors is: ...
(Date:7/11/2014)... News) -- Reducing the number of deer in an ... and other tick-borne infections among people, new research indicates. ... manipulated to reduce human interactions with deer, infected nymphal ... researchers wrote. White-tailed deer are the primary host ... people. The study included nearly all the permanent ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... Mississippi girl born with HIV who was thought to be ... new tests showing detectable levels of the AIDS-causing virus in ... girl, now nearly 4 years old, had remained virus-free even ... months old. Doctors had hoped her remission would open the ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3
... SAN FRANCISCO, Sept. 15 The Gladstone ... Quantitative Biomedical Research (QB3) at the University of California, ... (CDD) are pleased to announce the prestigious speakers and ... Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian ...
... (Sept. 15, 2009) A research project looking for ... of improving the bone health of cancer patients undergoing radiation ... microgravity environment of space causes bone loss in astronauts, but ... radiation on bones. Dr. Ted Bateman leads a project funded ...
... , , , ... the innovative healthcare company supporting the nation,s foremost cancer treatment and ... 2009 InformationWeek 500, an annual listing of the nation,s most innovative ... establishment of an enterprise-wide CRM platform. , , ...
... could improve long-term health, researchers say , TUESDAY, Sept. ... a greater risk of becoming obese in adulthood, new ... online Sept. 11 in the journal BMC Medicine ... Psychiatry Center at the Institute of Psychiatry at King,s ...
... , BURBANK, Calif., Sept. 15 ... Los Angeles and the Childrens Hospital Los Angeles Medical Group has ... treatment for a group that nationwide falls in a gap between ... The Adolescent & Young Adult Cancer Program ...
... Industries have ... million since ... and campaign ... and HMO political contributions and lobbying expenses found the industries spent $126,430,438 over the first half of 2009 and ...
Cached Medicine News:Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 2Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 3Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 4Health News:Space-related radiation research could help reduce fractures in cancer survivors 2Health News:Space-related radiation research could help reduce fractures in cancer survivors 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 2Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 3Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 4Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 5Health News:US Oncology Named to InformationWeek 500 as Top User of Business Technology 6Health News:Anxious Kids at Risk for Obesity in Adulthood 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 3Health News:Insurance and HMO Industries Spend Nearly $700,000 Per Day to Kill Health Care Reform Measures 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: